Is Daiichi Sankyo (4568) Halal?
Shariah Screening — 5 Standards
Based on financial data from March 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.9% / 30% | 13.6% / 30% | 11.7% / 30% | 1.81% / 5% | ✓ HALAL |
| DJIM | 1.9% / 33% | 13.6% / 33% | 11.7% / 33% | 1.81% / 5% | ✓ HALAL |
| MSCI | 2.9% / 33% | 20.9% / 33% | 17.9% / 33% | 1.81% / 5% | ✓ HALAL |
| S&P | 1.9% / 33% | 13.6% / 33% | 11.7% / 33% | 1.81% / 5% | ✓ HALAL |
| FTSE | 2.9% / 33% | 20.9% / 33% | 17.9% / 50% | 1.81% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 77.5% | |
| Operating Margin | 16.0% | |
| Net Margin | 14.8% | |
| Return on Equity (ROE) | 18.3% | |
| Return on Assets (ROA) | 5.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $53.8B |
| Free Cash Flow | -$134.0B |
| Total Debt | $101.3B |
| Debt-to-Equity | 17.6 |
| Current Ratio | 2.7 |
| Total Assets | $3.5T |
Price & Trading
| Last Close | JPY 2,874.50 |
| 50-Day MA | JPY 2,978.79 |
| 200-Day MA | JPY 3,419.48 |
| Avg Volume | 9.4M |
| Beta | -0.3 |
|
52-Week Range
JPY 2,684.00
| |
About Daiichi Sankyo (4568)
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment of symptomatic TGCT; Vanflyta, a FLT3 inhibitor to treat adult patients with acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and DATROWAY to treat adult patients with breast cancer and NSCLC. It also provides Liziana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo, an oral treatment that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia and Tenelia for the treatment of type 2 diabetes mellitus; Emgalty and Reyvow to treat migraine attacks; Pralia for the treatment of osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark to treat bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer to treat iron deficiency anemia; and Vimpat, an anti-seizure medication. Further, it provides vaccines for the treatment of COVID-19, influenza infections, adsorbed cell culture-derived influenza (H5N1) influenza infections, measles/rubella infections, and mumps infections. The company has a strategic collaboration with Lunit Inc. for the development of biomarker discovery and optimize translational research. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Chuo, Japan.
Purification Calculator
As a halal stock with 1.81% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Daiichi Sankyo (4568) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Daiichi Sankyo is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Daiichi Sankyo's debt ratio?
Daiichi Sankyo's debt ratio is 1.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.9%.
Does Daiichi Sankyo require dividend purification?
Yes, Daiichi Sankyo has an impermissible income ratio of 1.81%, which means 1.81% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Daiichi Sankyo's key financial metrics?
Daiichi Sankyo has a market capitalization of $5.4T, trailing P/E ratio of 19.6, and revenue of $1.9T. The company maintains a gross margin of 77.5% and a net margin of 14.8%. Return on equity stands at 18.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.